# Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Canonical URL: https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026
Ticker: DERM
Company: Journey Medical Corporation
Source: Journey Medical Corporation
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.journeymedicalcorp.com
## Summary

Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz.,…...

## Article Body
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10206557/103495af641 . Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com , and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com .

Company Contact: Jaclyn Jaffe Journey Medical Corporation (781) 652-4500 ir@jmcderm.com

Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com

Source: Journey Medical Corporation Released March 18, 2026
## Recent Company News
- 2026-06-25 13:46 EST — [Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Journey Medical Corporation
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)